You are here

Biomarin

10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says

10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says

BioSpace

Bristol-Myers Squibb

Flag link:

BioMarin's Novel Treatment Promises to Disrupt Competitors

BioMarin's Novel Treatment Promises to Disrupt Competitors

Motley Fool

Flag link:

FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review

FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review

Motley Fool

priority review

Flag link:

Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World

Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World

Forbes

Flag link:

BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy

BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy

Motley Fool

Flag link:

BioMarin sets gene therapy sights beyond hemophilia

BioMarin sets gene therapy sights beyond hemophilia

BioPharma Dive

Flag link:

These 3 Biotech Stocks Could Be Top Stocks in 2020

These 3 Biotech Stocks Could Be Top Stocks in 2020

Motley Fool

Flag link:

A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations

A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations

Yahoo/Benzinga

Bristol-Myers Squibb

Vertex Pharmaceuticals

Gilead Sciences

Flag link:

Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles

Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles

Fierce Pharma

drug manufacturing

Bristol-Myers Squibb

Sarepta Therapeutics

Gilead Sciences

Flag link:

Value-based pricing for gene therapy? Maybe not ready for hemophilia

Value-based pricing for gene therapy? Maybe not ready for hemophilia

Biopharma Dive

valoctocogene roxaparvovec

Flag link:

Here's Why BioMarin Pharmaceutical Leapt 10.2% in November

Here's Why BioMarin Pharmaceutical Leapt 10.2% in November

Motley Fool

Flag link:

The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict

The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict

Yahoo/Benzinga

Gilead Sciences

Edwards Lifesciences

Baxter International

Integra LifeSciences

Phathom Pharmaceuticals

Eton Pharmaceuticals

Melinta Therapeutics

Ligand Pharmaceuticals

Flag link:

BioMarin talks down worries on gene therapy data differences

BioMarin talks down worries on gene therapy data differences

Biopharma Dive

Flag link:

BioMarin's Roller Coaster Continues

BioMarin's Roller Coaster Continues

Yahoo/Motley Fool

Flag link:

BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end

BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end

Fierce Biotech

valoctocogene roxaparvovec

Flag link:

Billions on the line: BioMarin bustles past enthused rival, planning to launch world’s first hemophilia A gene therapy

Billions on the line: BioMarin bustles past enthused rival, planning to launch world’s first hemophilia A gene therapy

Endpoints

Flag link:

Sangamo backs up early success for hemophilia gene therapy

Sangamo backs up early success for hemophilia gene therapy

Biopharma Dive

Spark Therapeutics

Flag link:

How BioMarin May Revolutionize the Hemophilia Treatment Market

How BioMarin May Revolutionize the Hemophilia Treatment Market

Motley Fool

Flag link:

BioMarin Isn't a "Gene Therapy Company"

BioMarin Isn't a "Gene Therapy Company"

Motley Fool

Flag link:

Pages